Bio-Thera Solutions (SH: 688177) has partnered with STADA Arzneimittel (ETR: SAZ) for the commercialization of BAT2506, a biosimilar candidate to Simponi (golimumab).
Under the agreement, Bio-Thera will handle development and manufacturing, while STADA will manage commercialization in the EU, UK, Switzerland, and other countries.
Bio-Thera will receive an upfront payment of $10 million, with potential milestone payments up to $147.5 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze